News

Al-Mustaqbal University has announced that Professor Jabbar Faraj from the College of Pharmacy has achieved a remarkable scientific accomplishment on the global stage, following his success in developing a new pharmaceutical formulation of Fulvestrant inj in collaboration with a company during his work in the United States This development represents a significant step forward in the pharmaceutical industry, as the new formulation has contributed to enhancing the drug’s efficiency and making it easier for physicians, pharmacists, and patients to use. Among its key features are the ability to store it at room temperature, the reduction of most potential side effects such as hair loss and nausea, as well as the option of administering it once a month via intramuscular injection, making it more convenient and acceptable for patients The drug has been officially registered in the United States as a developed formulation and received approval from the U.S. Food and Drug Administration (FDA) in July 2025. It has also been listed under U.S. patents with the title FULVESTRANT FORMULATIONS Al-Mustaqbal University praised this significant achievement, which reflects the scientific standing of its faculty and their ability to contribute to innovation and research at the international level. The university expressed its pride in Professor Jabbar Faraj’s excellence and wished him continued success and progress in his academic and research career